Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Yanzhen Zhang; Huaigang Chen; Lang Hong; Hong Wang; Bin Li; Mengyin Zhang; Jiamei Li; Liu Yang; Fan Liu

doi:10.3389/fphar.2023.1260921

Inclisiran: a new generation of lipid-lowering siRNA therapeutic

Front Pharmacol. 2023 Oct 13:14:1260921. doi: 10.3389/fphar.2023.1260921. eCollection 2023.

Authors

Yanzhen Zhang¹, Huaigang Chen^{2

3}, Lang Hong³, Hong Wang³, Bin Li³, Mengyin Zhang⁴, Jiamei Li⁵, Liu Yang³, Fan Liu⁶

Affiliations

¹ Department of Rheumatology, Shunyi Hospital, Beijing Traditional Chinese Medicine Hospital, Beijing, China.
² Medical College of Nanchang University, Nanchang, China.
³ Department of Cardiology, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
⁴ Pharmacy Department, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
⁵ Laboratory Department, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
⁶ Department of Hematology Jiangxi Hospital of Traditional Chinese Medicine, Nanchang, China.

Abstract

Atherosclerotic heart disease (AHD) is a major cause of morbidity and mortality worldwide. Lowering low-density lipoprotein cholesterol (LDL-C) levels is a key strategy to prevent and treat AHD. Inclisiran is a novel siRNA drug that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) gene expression and reduces LDL-C levels with only two or three injections per year. This review summarizes the mechanism, efficacy, safety, and applications of Inclisiran in various populations and settings, based on recent literature. It also compares Inclisiran with other lipid-lowering drugs, especially other PCSK9 inhibitors. We conclude that Inclisiran is a promising lipid-lowering agent that can provide convenience and effectiveness for patients with high cardiovascular risk. However, some challenges and limitations remain for Inclisiran, such as its long-term safety and efficacy, its cost-effectiveness and accessibility, and its interactions and synergies with other drugs. These issues need further investigation and evaluation in future studies.

Keywords: Inclisiran; PCSK9; cardiovascular risk; lipid-lowering therapies; siRNA.

Publication types

Review

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. Key Program of Jiangxi Provincial Health Commission, Coronary Atherectomy for the Treatment of Coronary Artery Disease; Project Number: 20-021 (to LH). Doctor Start-up fund of Jiangxi provincial People’s Hospital, The First Affiliated Hospital of Nanchang Medical College (No. 19-236) (to LY). Application and Promotion of Regional Collaborative Medical Treatment Platform for Acute Cardiovascular Events in Jiangxi Province; Key Research and Development Program of Jiangxi Province; Project Number: 20161BBG70116 (to HW).